Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) EBITDA: 2016-2024

Historic EBITDA for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to -$421.4 million.

  • Denali Therapeutics' EBITDA fell 0.07% to -$118.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$421.4 million, marking a year-over-year decrease of 206.04%. This contributed to the annual value of -$421.4 million for FY2024, which is 206.04% down from last year.
  • According to the latest figures from FY2024, Denali Therapeutics' EBITDA is -$421.4 million, which was down 206.04% from -$137.7 million recorded in FY2023.
  • Over the past 5 years, Denali Therapeutics' EBITDA peaked at $70.5 million during FY2020, and registered a low of -$421.4 million during FY2024.
  • For the 3-year period, Denali Therapeutics' EBITDA averaged around -$296.5 million, with its median value being -$330.4 million (2022).
  • As far as peak fluctuations go, Denali Therapeutics' EBITDA skyrocketed by 135.88% in 2020, and later tumbled by 515.13% in 2021.
  • Yearly analysis of 5 years shows Denali Therapeutics' EBITDA stood at $70.5 million in 2020, then plummeted by 515.13% to -$292.8 million in 2021, then decreased by 12.82% to -$330.4 million in 2022, then surged by 58.32% to -$137.7 million in 2023, then slumped by 206.04% to -$421.4 million in 2024.